Last reviewed · How we verify
Part 1: JNJ-42756493
At a glance
| Generic name | Part 1: JNJ-42756493 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer (PHASE1, PHASE2)
- A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma (PHASE1)
- Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part 1: JNJ-42756493 CI brief — competitive landscape report
- Part 1: JNJ-42756493 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI